Oculis Holding AG Cuts Target to $38 After Trial Failure, Holds $278M Cash
OCS•Robert W. Baird cut its price target for Oculis Holding AG to $38 from $49 after its lead drug candidate OCS-01 failed the primary endpoint in Phase 3 DIAMOND trials for diabetic macular edema. The company holds $278 million in cash, funding operations into 2029 while refocusing its pipeline during a probe.
1. Price Target Reduction and Trial Failure
Robert W. Baird cut its price target to $38 from $49 after OCS-01 failed to meet the primary endpoint in Phase 3 DIAMOND trials for diabetic macular edema, prompting a 23.4% stock decline in a single trading day.
2. Financial Position and Cash Runway
Oculis Holding AG reported $278 million in cash and short-term investments as of March 31, 2026, providing funding for operations into the second half of 2029 despite the setback.
3. Securities Probe Initiated
Law firm Levi & Korsinsky launched an investigation into potential securities law violations, examining whether Oculis misled investors about the progress of the OCS-01 DME program prior to the share collapse.
4. Strategic Reorientation of Pipeline
Following the trial failure, the company halted FDA filing plans for OCS-01 in diabetic macular edema and will reallocate resources toward other programs, including optic neuropathies and dry eye disease candidates.
Related News
Digital Brands Group Announces 1-For-40 Reverse Stock Split To Solidify Continued Nasdaq Compliance Reduces Outstanding Common Stock Float To Approximately 557,000 Shares
Two oil tankers exploded after passing through mined route south of Strait of Hormuz, Iran's state TV reports
